RxDoctor Payments Data

Eddie Hu, MD

Hematology-Oncology · Alhambra, CANPI 1871537738

Payments from drug & device makers

What this record shows

This record is dominated by other: $1,548 of the $1,839 with a category attached, or 84.2%. Novartis accounts for 86.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $1,062 and has fallen 98.3% since, to $18 in 2025. That places this record below the midpoint for hematology-oncology clinicians in CA, where the typical reported total is $1,839.

$1,839in general payments, 2019–2025

Across 29 payments — averaging $63.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Pharmacyclics LLC, An Abbvie Company$100
  • AstraZeneca$40
  • Pfizer$40
  • Johnson & Johnson$22
  • Merck$18
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$1317%
  • Education$1609%
  • Other$1,54884%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,839 in reported general payments places this provider in the 50th percentile of 53 hematology-oncology providers in California.

See all hematology-oncology providers in California

Medicare billing

Part B allowed, 2024
$2,400,498
Medicare patients
814
Services billed
86,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate206$3,438,301
ImbruvicaIbrutinib29$672,974
TepmetkoTepotinib Hcl21$513,278
RevlimidLenalidomide28$445,144
KisqaliRibociclib Succinate23$388,950
PromactaEltrombopag Olamine28$360,894
XtandiEnzalutamide23$320,713
JakafiRuxolitinib Phosphate15$279,738
AlecensaAlectinib Hcl12$232,255
XgevaDenosumab66$214,257
CalquenceAcalabrutinib Maleate14$213,856
BrukinsaZanubrutinib15$201,818
MekinistTrametinib Dimethyl Sulfoxide12$185,997
ReblozylLuspatercept-Aamt13$180,273
ErleadaApalutamide12$179,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso, Calquence$40$3,652,157220 claims
NovartisKisqali, Promacta, Mekinist, Tafinlar$1,592$1,105,43575 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$100$672,97429 claims
Johnson & JohnsonErleada, Procrit, Xarelto$22$350,34759 claims
PfizerInlyta, Eliquis$40$258,423122 claims
Beigene USA, Inc.Brukinsa$14$201,81815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 53 hematology-oncology providers in California.

Other hematology-oncology in Alhambra

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →